Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Square Sets IPO Price at $9 a Share, Making It Much Less Valuable Than It Was Last Year

Not the best debut.

Vox
Jason Del Rey
Jason Del Rey has been a business journalist for 15 years and has covered Amazon, Walmart, and the e-commerce industry for the last decade. He was a senior correspondent at Vox.

Square, the small-business payments and services company run by Jack Dorsey, set an IPO price of $9 a share this evening, falling below the initial price range it set of $11 to $13 a share. The price also marks a 42 percent discount from the $15.46 a share investors paid in Square’s last round of private financing in 2014.

The $9 a share tells us that demand among investors was lower than Square and its bankers anticipated. In other words, Wall Street and Silicon Valley have very different ideas of its future value. It also means, simply put, that Square is worth much less than it was last year on the private markets. In addition, big institutional investors likely asked for a discount in the offering, given all the open questions about startup financing in general and Square’s business in particular.

Square’s revenue, mainly composed of payment processing fees for retail businesses, is growing fast, but the company still records heavy losses. One common question from investors is how Square will eventually become profitable. The fact that Dorsey is also the full-time CEO of Twitter could be weighing on investors’ minds as well.

Square sold 27 million shares in the IPO, raising $243 million in the offering. The $9 share price also means that Square will have to issue millions of extra shares to its Series E investors under the terms of that fundraising deal. Those investors paid $15.46 a share, but would be owed extra shares if Square’s IPO share price was less than $18.55, which it is. Square will have to issue these Series E investors more shares to make up the difference. That’s a better deal than what was offered to Series D investors, who paid $11.01 a share but didn’t get the same price protection, what’s known as a “ratchet,” for their investment.

The IPO price is what big institutional investors such as mutual funds dish out for shares. The price could rise or fall by the time the stock becomes available to mainstream investors on the New York Stock Exchange on Thursday morning.

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh